| 000 | 04347naa a22005777i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-059 | ||
| 003 | local | ||
| 005 | 20261005174906.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2024 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.32604/or.2024.050350 _2doi |
|
| 035 | _a(local)EuropePMC:PMC11209743 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aPaulina Chmiel _eauthor. |
|
| 245 | 1 | 0 |
_aInflammatory myofibroblastic tumor from molecular diagnostics to current treatment. / _cPaulina Chmiel; Aleksandra SłOWIKOWSKA; Łukasz Banaszek [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _bTech Science Press, _c2024. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aInflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy. | |
| 540 |
_aCreative Commons Attribution. See the linked licence for the applicable terms. _uhttps://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 650 | 4 | _aAnaplastic Lymphoma Kinase (Alk) | |
| 650 | 4 | _aInflammatory Myofibroblastic Tumor (Imt) | |
| 650 | 4 | _aTyrosine Kinase Inhibitors (Tki) | |
| 650 | 4 | _aEpithelioid Inflammatory Myofibroblastic Sarcoma | |
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _amolecular diagnostics | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aAleksandra SłOWIKOWSKA _eauthor. |
|
| 700 | 0 |
_aŁukasz Banaszek _eauthor. |
|
| 700 | 0 |
_aAnna Szumera-CIEćKIEWICZ _eauthor. |
|
| 700 | 0 |
_aBARTłOMIEJ Szostakowski _eauthor. |
|
| 700 | 0 |
_aMateusz J SPAłEK _eauthor. |
|
| 700 | 0 |
_aTomasz Świtaj _eauthor. |
|
| 700 | 0 |
_aPiotr Rutkowski _eauthor. |
|
| 700 | 0 |
_aAnna M Czarnecka _eauthor. |
|
| 773 | 0 |
_tOncology research _gVol. 32, no. 7, (2024), pages/article 1141-1162 _x0965-0407 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC11209743 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC11209743 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1201 _d1201 |
||